Dietrich John Pauls net worth and biography

Dietrich Pauls Biography and Net Worth

Rick Pauls was appointed our President and Chief Executive Officer in July 2009. Mr. Pauls has served as a member of our board of directors since April 2005 and as the Chairman of the Board from April 2008 to July 2014.

Before joining DiaMedica, Mr. Pauls was the Co-Founder and Managing Director of CentreStone Ventures, an early-stage life sciences venture capital fund, from February 2002 until January 2010. Mr. Pauls was an analyst for Centara Corporation, an early-stage venture capital fund, from January 2000 until January 2002. From June 1997 until November 1999, Mr. Pauls worked for General Motors Acceptation Corporation specializing in asset-backed securitization and structured finance. Additionally, Mr. Pauls has served on the board of directors of several public and private companies. Mr. Pauls received his B.A. in Economics from the University of Manitoba and his M.B.A. in Finance from the University of North Dakota.

What is Dietrich John Pauls' net worth?: The estimated net worth of Dietrich John Pauls is at least $336,095.90 as of June 23rd, 2023. Mr. Pauls owns 68,591 shares of DiaMedica Therapeutics stock worth more than $336,096 as of December 18th. This net worth approximation does not reflect any other investments that Mr. Pauls may own. Additionally, Mr. Pauls receives an annual salary of $818,610.00 as CEO at DiaMedica Therapeutics. Learn More about Dietrich John Pauls' net worth.
How old is Dietrich John Pauls?: Mr. Pauls is currently 53 years old. There are 5 older executives and no younger executives at DiaMedica Therapeutics. Learn More on Dietrich John Pauls' age.
What is Dietrich John Pauls' salary?: As the CEO of DiaMedica Therapeutics Inc., Mr. Pauls earns $818,610.00 per year. Learn More on Dietrich John Pauls' salary.
How do I contact Dietrich John Pauls?: The corporate mailing address for Mr. Pauls and other DiaMedica Therapeutics executives is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. DiaMedica Therapeutics can also be reached via phone at (763) 496-5454 and via email at [email protected]. Learn More on Dietrich John Pauls' contact information.
Has Dietrich John Pauls been buying or selling shares of DiaMedica Therapeutics?: Dietrich John Pauls has not been actively trading shares of DiaMedica Therapeutics within the last three months. Most recently, on Friday, June 23rd, Dietrich John Pauls bought 12,787 shares of DiaMedica Therapeutics stock. The stock was acquired at an average cost of $3.91 per share, with a total value of $49,997.17. Following the completion of the transaction, the chief executive officer now directly owns 68,591 shares of the company's stock, valued at $268,190.81. Learn More on Dietrich John Pauls' trading history.
Who are DiaMedica Therapeutics' active insiders?: DiaMedica Therapeutics' insider roster includes Harry Alcorn, Jr. (VP), Dietrich Pauls (CEO), and Richard Pilnik (Director). Learn More on DiaMedica Therapeutics' active insiders.
Are insiders buying or selling shares of DiaMedica Therapeutics?: During the last twelve months, DiaMedica Therapeutics insiders bought shares 1 times. They purchased a total of 1,200,000 shares worth more than $3,000,000.00. The most recent insider tranaction occured on June, 28th when Major Shareholder Koch Thomas Von bought 1,200,000 shares worth more than $3,000,000.00. Insiders at DiaMedica Therapeutics own 7.2% of the company. Learn More about insider trades at DiaMedica Therapeutics.
Information on this page was last updated on 6/28/2024.

Dietrich John Pauls Insider Trading History at DiaMedica Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/23/2023	Buy	12,787	$3.91	$49,997.17	68,591
11/16/2022	Buy	20,000	$1.21	$24,200.00	55,804
8/16/2021	Buy	5,000	$3.14	$15,700.00
8/16/2019	Buy	1,000	$2.68	$2,680.00

Dietrich John Pauls Buying and Selling Activity at DiaMedica Therapeutics

DiaMedica Therapeutics Company Overview

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Today's Range

Now: $4.82

$4.78

$5.30

50 Day Range

MA: $4.64

$4.01

$5.66

2 Week Range

Now: $4.82

$2.14

$5.74

Volume

116,292 shs

Average Volume

59,079 shs

Market Capitalization

$206.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.51

From Behind the Markets | Ad

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol

Dietrich Pauls Biography and Net Worth

What is Dietrich John Pauls' net worth?

How old is Dietrich John Pauls?

What is Dietrich John Pauls' salary?

How do I contact Dietrich John Pauls?

Has Dietrich John Pauls been buying or selling shares of DiaMedica Therapeutics?

Who are DiaMedica Therapeutics' active insiders?

Are insiders buying or selling shares of DiaMedica Therapeutics?